Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes

Core Points - Lucid Diagnostics Inc. will be added to the small-cap Russell 2000® Index and the broad-market Russell 3000® Index effective after the close of U.S. equity markets on June 27, 2025, as part of the 2025 annual reconstitution [1][2] - This inclusion is expected to enhance Lucid's visibility and access to a broader range of institutional investors, reflecting the company's progress in enhancing shareholder value over the past year [2] Company Overview - Lucid Diagnostics is a commercial-stage cancer prevention medical diagnostics company and a subsidiary of PAVmed Inc., focusing on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer [4] - The company's EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device are the first and only commercially available tools aimed at preventing cancer through early detection of esophageal precancer in at-risk patients [4] Market Context - The Russell 3000 Index includes the largest 3,000 U.S. public companies by market capitalization, while the Russell 2000 Index is a subset focused on small-cap companies [2] - Approximately $10.6 trillion in assets are benchmarked against the Russell U.S. Indexes, indicating the significance of these indices for institutional investors and investment managers [2]